Positive study results for Prothena By: MarketMinute.com Stock News March 20, 2015 at 11:39 AM EDT Prothena Corp. (Nasdaq: PRTA) reported positive results from a Phase 1 study of its Parkinson's disease treatment PRX002 sending the stock price soaring $11.17 to $40.40. Related Stocks: Prothena Corp